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The Impact of Frailty on Health Related Quality of Life in Heart Failure
Abstract
Background/Aims: Most heart failure (HF) hospital discharges involve people > 65 years, many frail. The
purpose of this study was to determine if frailty explains variability in health related quality of life (HRQOL)
in older adults with HF over and above known correlates.
Methods: A frailty index score was developed by weighting age, number of comorbid conditions, and
symptom severity. A multivariate hierarchical regression analysis of known predictors of HRQOLgender,
income, ethnicity, health perception, NYHA class — were entered first and then the frailty index was
entered and regressed on HRQOL in 2 unique samples.
Results: When known predictors were tested on a sample they explained 11% (p 0.14) of the variance in
HRQOL; when the frailty index score was added 24% (p 0.001) was explained. When the index was
validated in a second sample, known predictors explained 15% (p 0.04) of the variance; with the frailty
index score 40% (p 0.000) was explained.
Conclusion: Frailty explains significant amounts of variance in HRQOL in HF. Treating comorbid
conditions and controlling symptoms may improve HRQOL in HF patients. These findings support the
need for further research into the impact of frailty on HRQOL in HF patients.
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Abstract
Background/Aims: Most heart failure (HF) discharges involve people > 65 years, many frail.
The purpose of this study was to determine if frailty explains variability in health related quality
of life (HRQOL) in older adults with HF over and above known correlates.

Methods: A frailty index score was developed by weighting age, number of comorbid
conditions, and symptom severity. A multivariate hierarchical regression analysis of known
predictors of HRQOL- gender, income, ethnicity, health perception, NYHA class – were entered
first and then the frailty index was entered and regressed on HRQOL in 2 unique samples.
Results: When known predictors were tested on a sample they explained 11% (p 0.14) of the
variance in HRQOL; when the frailty index score was added 24% (p 0.001) was explained.
When the index was validated in a second sample, known predictors explained 15% (p 0.04) of
the variance; with the frailty index score 40% (p 0.000) was explained.
Conclusion: Frailty explains significant amounts of variance in HRQOL in HF. Treating
comorbid conditions and controlling symptoms may improve HRQOL in HF patients. These
findings support the need for further research into the impact of frailty on HRQOL in HF
patients.

Keywords : index score, regression, predictors of HRQOL, frailty

Introduction
Globally, cardiovascular disease (CVD) is the number one cause of morbidity and
mortality in both developed and developing countries1. In the United States2 (US) and most
European countries1 CVD is also a disease of aging. Almost two thirds of the six million people
discharged from the hospital in the US with CVD are 65 years of age or older2. In particular,
73% of those discharged with the diagnosis of heart failure (HF) were over the age of 65 2. The
development of a chronic syndrome, like HF, can precipitate concurrent frailty3. Frailty, defined
as a state of risk or vulnerability brought about by co-occurring, multiple system deterioration
resulting in adverse outcomes, is highly prevalent in the older adult population 3-6. Because
multiple systems are compromised and regulating one system may affect another, frail, older
adults with HF are at risk for increased hospitalizations7. A further negative outcome common is
poor health related quality of life (HRQOL), an issue that is already particularly problematic for
older adults with HF 8. Frail older adults with HF are frequently hospitalized increasing their
risk for additional deficits.
Each one of these older adults hospitalized with HF was cared for by a nurse, many of
whom specialize in cardiovascular nursing. Cardiovascular nurses also provide expert care to
HF patients in outpatient settings. But are these nurses equally prepared to recognize frailty and
care for older adults? While frailty has been studied and discussed extensively in the geriatric
literature, reference to frailty is limited in the cardiovascular literature 3, 5, 6. Further exploration
is needed to determine whether there is a relationship between frailty and HRQOL, individually
and in relation to both morbidity and mortality 4, 9, 10. Therefore, the purpose of this study was to
explore the relationship between frailty and HRQOL in older HF patients.

Frailty in Heart Failure
Frailty is currently understood in one of two ways. One way defines frailty as a clinical
syndrome based on selected physical indicators resulting in vulnerability 4. A second way
defines frailty as a multi-factorial state of deficits accumulated over the life course 3. Fried and
colleagues 4 developed a phenotype of frailty using data from the Cardiovascular Health Study.
Frailty, as a clinical syndrome, was said to be present if a person presented with three or more of
the following symptoms: an unintentional weight loss of 10 lbs in the past year, weakness
measured via grip strength, fatigue, decreased activity, or slowed walking speed. In
cardiovascular samples, frailty is most commonly found in those with multiple comorbid
conditions11. About half of a community dwelling sample of over 5,000 older persons met the
criteria for frail (3 or more indicators) or near frail (1 or 2 indicators). Frailty was associated
most strongly with age and a history of HF (odds ratio 7.51, 95% confidence interval 4.66 –
12.12) 12. In another study of 670 community dwelling women, cardiovascular disease (CVD)
increased the risk of frailty in those with mild anemia. A significant multiplicative interaction
was found between hemoglobin level and CVD status with respect to the risk of frailty when
controlling for age and other covariates. Chaves and colleagues 13 theorized that CVD
diminished the effectiveness of compensatory responses to anemia resulting in increased
vulnerability.
Frailty is associated with disability but differentiated by its biologic antecedents of
decreased physiologic reserve and resistance to stressors, while disability is understood to
involve an inability to perform certain activities. Fried and colleagues 4 found only a modest
concordance between frailty and disability but that there was a significant stepwise increase in

disability as frailty increased. In persons with HF, frailty has been found to predict falls,
disability, hospitalization, and death 4, 9.
Health Related Quality of Life in Heart Failure
HRQOL is a subjective, multidimensional construct that links physical, psychological,
and social well-being with the ability to carry out the activities of daily living 14. In HF,
subjective variables like symptoms, functional status, anxiety and health perception are
consistently associated with HRQOL with more symptoms, poorer functional status, greater
anxiety scores and poor health perception associated with poorer HRQOL 15-19. More objective
indices like ejection fraction, B-type natriuretic peptide (BNP), and jugular venous distention
have not been found to have a direct effect on HRQOL 17, 18.
HRQOL impacts morbidity, mortality, and treatment choices for patients. In a Spanish
sample, worsening HRQOL predicted hospital readmission and mortality for HF patients at a
frequency comparable to other well known predictors such as a history of diabetes or treatment
with an angiotensin converting enzyme inhibitor 10.

Patients with poorer HRQOL are more

willing to trade survival time and take risks in treatment choices than those with better HRQOL
20, 21

.
From the literature it can be theorized that there is a relationship between frailty and

HRQOL. The relationship between frailty and disability4 in addition to the relationship between
functional status and HRQOL8 supports the hypothesis that there would be a relationship
between frailty and HRQOL. However, no study was found that examined this hypothesis.
Therefore, in this secondary analysis we explored this relationship between frailty and HRQOL
in persons with HF after accounting for known determinants of HRQOL.

Building on our previous work which was tested in another end stage disease population,
we continue to explore whether a framework in which quality of life is the primary outcome is
applicable in other disease populations22. In this framework variability in HRQOL is explained
by both fixed and modifiable dimensions of the domains of the patient’s lived experience. The
domains are physiological, psychological, social/cultural, and spiritual/existential. The measured
indicators for the fixed dimensions need to be accounted for but the indicators for the modifiable
dimensions, depending on whether they directly or inversely impact HRQOL, need to be either
supported or ameliorated. For this study frailty is conceptualized as including indicators for both
fixed and modifiable dimensions for the physiological domain – the patient’s age and number of
comorbid conditions are fixed while symptom severity is modifiable and therefore amenable to
interventions focused on improving quality of life.
Methods
In this secondary analysis frailty was conceptualized as a construct measured using the
person’s age at time of enrollment into the study, number of comorbid conditions, and a total
severity score for three symptoms prevalent in this population – fatigue, dyspnea on exertion,
and chest pain. Age was obtained by self-report. Comorbid conditions were measured using the
17-item Charlson Comorbidity Index, which generates a total possible score ranging from 0-30.
A higher score indicates a higher level of comorbid disease 23. The symptom scale asked the
person to rank each symptom (fatigue, dyspnea on exertion, chest pain) on a 1-10 scale with the
anchors, 1 = very mild and 10 = worst imaginable. Zero was entered if the symptom was not
reported.
The index was formed by weighting these three indicators (age, comorbidity, symptoms)
using weights derived from an analysis performed in a benchmark sample of 130 older adults

with HF who had been accrued for a previous intervention study24. The individual items were
regressed on the total Minnesota Living with Heart Failure Questionnaire (MLHFQ) score and
then the unstandardized coefficients and the constant from that regression were used to derive the
weights for the new frailty index. Potential contamination between the MLHFQ score and the
three indicators was assessed by examining collinearity statistics. Residual statistics and
influence were also analyzed. The regression equation was Predicted MLHFQ total score = (66
+ (age x -0. 597) + (symptom severity x 1.426) + (comorbidity score x 1.38)). The index was
then confirmed in a second sample which was split into two unique groups to test and validate
the stability of the findings. Known determinants of HRQOL were accounted for in all analyses.
Sample
The benchmark sample participants were accrued from two Southern California hospitals
24

. The test sample was from five hospitals in the same area 25. The recruitment of the

participants and procedures have been described in detail elsewhere, but in brief, HF patients
were enrolled during hospitalization, half received a disease management intervention, and all
were followed for 6 months24, 25. The test sample was divided in half with one half used to test
the index (Test sample one) and the second half used to validate the stability of the index (Test
sample two). Both the benchmark and test samples were hospitalized with a primary diagnosis
of HF at the time of enrollment and able to speak English or Spanish. Patients with an obvious
cognitive impairment, an untreated psychiatric illness, or a terminal disease, were excluded as
were those on renal dialysis and those being discharged to a long term care facility. Only
baseline data collected at enrollment were used to develop and test the frailty index. This
investigation conformed with the principles outlined in the Declaration of Helsinki26.
Measurement

HRQOL was measured by the total score on the MLHFQ 27. The MLHFQ, used widely
in HF research, asks the person to rate the impact (0 = no impact to 5 = most severe impact) of
their condition or its treatment on various aspects of daily life. The items are additive, yielding a
total score of 0-105, with a lower score reflecting less impact or better HRQOL. For this study
the Cronbach’s alpha for the two test samples was 0.92.
Demographics (i.e. gender, ethnicity, marital status, education level, work status, and
income) were obtained by self-report. Health perception was measured by a one item question
asking the person to rate his or her health (1 = much worse to 5 = much better) as compared with
a year ago.
Data Analysis
Multivariate hierarchical regression modeling was conducted using SPSS version 15.0 28.
Predictors of HRQOL were identified from the literature. Two model blocks (1st block: NYHA
class, ethnicity, income, health perception, and gender; 2nd block: new frailty index) were tested
with HRQOL as the dependent variable on Test sample one and then validated with Test sample
two. A p value of less than 0.05 was accepted as statistically significant. Collinearity statistics
and residual statistics were scrutinized.
Results
Characteristics of the Sample
In the benchmark sample used to develop the frailty index, a total of 130 older adults,
median age 72 years, 98% NYHA III or IV HF were included. Test sample one included a total
of 97 unique persons, median age 76 years, 87% NYHA class III or IV HF. Test sample two
included 75 additional persons, median age 72 years, 92% NYHA class III or IV HF. In the test
sample participants were likely to be female, married, white, retired, finished high school, and

lower income. Differences between the benchmark sample and the test sample were analyzed
using chi square with a Bonferroni adjustment to control for Type I errors, a p of 0.007 was
necessary for significance. Individuals in the benchmark sample were more likely than the two
test samples to be Hispanic, NYHA Class IV, with less than a 7th grade education, and make
under $10,000 (US ) a year in income. See Tables 1 and 2 for additional demographic
information and the means (standard deviations) on the frailty index for all samples.
Effect of Known Predictors and Frailty Index on HRQOL
For the benchmark sample, the zero-order and partial correlations for age show that when
symptoms (fatigue, dyspnea, and chest pain) and number of comorbid conditions are controlled,
age has less influence on MLHFQ total (Table 3). Similar findings result for symptoms when
controlling for age and comorbidity as well as for comorbidity when age and symptoms are
controlled. The semi-partial correlations show that when assessing the unique amount of
variance accounted for by age, symptoms, or comorbidity on MLHFQ total, age and symptoms
continue to show a moderate amount of correlation. Due to this moderate correlation,
collinearity statistics were examined before the analysis continued. Tolerance and its inverse
(variance inflation factor) are within accepted limits (Table 3). The same analysis was
conducted on Test sample one and Test sample two. Inspection of the residual statistical output
for the benchmark sample showed that while at least one prediction was more than two standard
deviations below the mean residual(-2.45) there was no undue influence exerted with maximum
leverage of 0.09. In Test sample one the standardized residual was -2.18 (max leverage 0.54)
and for Test sample two the standardized residual was -2.36 (max leverage 0.52).
Using multivariate hierarchical regression, known predictors of HRQOL - NYHA class,
ethnicity, income, health perception, and gender were regressed upon the total MLHFQ score in

the first block. The frailty index was then entered in the second block. In Test sample one and
two the frailty index significantly increased the amount of variability predicted for HRQOL
(Table 4). The standardized β show that when the other predictors are held constant that
MLHFQ total score will, on average, increase 0.37 SD (Test sample one) and 0.54 SD (Test
sample two) when the frailty index increases one standard deviation. A higher MLHFQ total
score denotes lower HRQOL for the patient.
Discussion
In this study we examined the relationship of frailty and HRQOL in older adults with HF.
We found that when frailty was measured as a composite of age, number of comorbid conditions,
and symptom status a significant amount of variability in HRQOL was explained over and above
know determinants of HRQOL. While 627 publications were found citing Fried and colleagues 4
seminal work on developing a phenotype of frailty in the geriatric population, this is the first
study of HRQOL and frailty in community dwelling older adults with HF. This study supports
the importance of nurses being aware of and assessing the risk for frailty in older adult with HF
but it also provides easily obtained indicators for assessing for the presence of frailty in their
patients. When these frailty indicators are present the nurse can then implement evidence based
best practice protocols to address the risk to decreased quality of life that they represent. This
frailty index combines both current conceptualizations of frailty (clinical syndrome,
multifactorial state) into a clinically useful measurement.
Age and frailty are linked but distinct phenomena 3, 6. Heterogeneity in the older adult
population may account for the differences between age and frailty. While older adults with HF
report poorer HRQOL than age matched healthy groups 8 it is less clear whether age alone
effects HRQOL in HF. As this study showed, when number of comorbid conditions and

symptoms were held constant the influence of age decreased. Two recent studies in HF
populations found that while not the strongest predictor, age, did predict HRQOL when analyzed
with other independent variables – with older patients reporting better HRQOL29, 30. This
finding is supported in other disease populations, such as oncology, where older adults generally
report higher quality of life and less symptom distress even when they have greater numbers of
comorbid diseases and more symptom burden than younger persons at the same disease stage 31,
32

. The weighting of age in this index shows that it is less explanatory of frailty than the other

two indicators – number of comorbid conditions and symptom severity.
Conceptually, comorbidity has been suggested as a mediator between physiological
processes and clinical outcomes 33. HF patients are also known to be more likely to have
diabetes11, renal failure34, and depression35 in addition to other comorbidities36. The number of
comorbid conditions is known to be related to frailty 4, 37. Perhaps the metabolic stress placed
on the body by multiple disease processes in the presence of diminishing metabolic reserves may
potentiate the osteopenia and sarcopenia noted as hallmarks of frailty38. In this study the number
of comorbid conditions contributes more to the frailty index than age but not as much as
symptom severity.
It has been suggested that chronic symptoms are seen by the older adult as normal in
aging 32. However, in this study we showed that rating higher severity on the three symptoms
found most frequently in HF – fatigue, dyspnea on exertion, and chest pain – contribute to
frailty, perhaps by limiting activity, which may set up a negative feedback system whereby the
decreased activity leads to greater risk for increased frailty and decreased HRQOL. Morley,
Perry, and Miller 38 have developed a model to explain the etiology of frailty in older adults.
They proposed that pain is one precursor that leads to inactivity, then sarcopenia, and finally,

frailty. Additional etiologic factors suggested are malnutrition, atherosclerosis, cognitive
impairment and social factors38. The relationships between age, symptoms, and HRQOL found
in this study is supported by previous work conducted in adults with HF by Heo and colleagues
29

.
While there is extensive literature on quality of life in the oncology and geriatric

populations, in comparison, there is a paucity of work exploring the predictors of HRQOL in
cardiac patients. Prior to 2000, HRQOL was a rare primary endpoint in HF clinical trial14, 39. In
the intervening years, those studies that have assessed HRQOL found poorer HRQOL to be
directly or indirectly associated with NYHA functional class, depression, number of medications,
serum creatinine, and lower ejection fraction 10, 15, 17, 40. Together, these isolated predictors could
be thought of as indicators of frailty, a conceptual leap that would move the field forward.
Bekelman and colleagues 16, in a NYHA class II population, found 32% of the variance
in HRQOL was explained by the number of symptoms. Our study supports the increasing
importance of the symptom experience as the individual declines by using a mostly NYHA class
III and IV population, while also accounting for two other well known predictors of HRQOL –
age and number of comorbid conditions. Bekelman used the Memorial Symptom Assessment
Scale –short form (MSAS) which assesses the presence, severity, and distress caused by 25
symptoms common in patients. It is interesting to note that while the version of the MSAS used
by these researchers was not developed for cardiac patients, the top three symptoms reported in
Bekelman’s study were shortness of breath, lack of energy, and pain (area not specified). Our
symptom severity score included fatigue and shortness of breath while assessing for specific
cardiac (chest) pain.

Heo and colleagues found that gender, work status, affective state, and symptom status
all predicted HRQOL 8, 18, 41. Furthermore, subjective variables – health perception and symptom
status, were stronger predictors of HRQOL than more objective variables like disease etiology
and number of comorbidities. A model inclusive of a single item health perception question,
symptom status, and age explained 29% of the variance in the total MLHFQ 18. The difference
in the findings between our study and Heo and colleagues’ may be related to the developed
frailty index. Age, symptom severity, and number of comorbid conditions are weighted
differently to reflect their known influence on HRQOL.
Quality of life has been described as reflecting the totality of the individual’s experiences
and perceptions over time but also to depend on the time at which it is measured 42. As to
whether subjective quality of life is a state (situationally determined) or trait (dispositionally
determined) measure needs further exploration. Cummins 43 suggests that each individual has a
normative level of subjective well-being which is generally positive and insensitive to gradual
and low levels of degradation. However, he suggests that current atheoretical
conceptualizations and poor measurement of quality of life hinder the advancement of the
science.

Cummins goes on to recommend that further work in the area include: 1) agreement

in quality of life measurement as to which variables are indicator and which are causal, 2)
organization of indicator variables hierarchically from general to specific, and 3) development of
instruments based on this hierarchy. Our study addressed these two critiques of quality of life
research by designing the study based on a conceptual model and using a well validated
instrument (MLHFQ) to measure quality of life.
One strength of this study is its theoretical foundation. Previous work on the conceptual
framework had shown that QOL was directly and inversely related to fixed and modifiable

dimensions of the older adult’s disease experience domains (physiological and
spiritual/existential) in an oncology population22. When this study was designed, HRQOL was
conceptualized as an outcome variable explained by similar fixed and modifiable dimensions of
the physiological domain in a HF population. The relationship of HRQOL and frailty (measured
as a composite of age, number of comorbid conditions, and symptom severity) was theorized a
priori to be negatively related based on the literature and this conceptual framework. The
findings of the data analyses in this study supported these hypotheses. As frailty increases,
HRQOL decreases. While this study was conducted in one end stage disease population –
individuals with HF, it is recommended that the index be tested in other populations to broaden
its applicability.
A further strength relates to the methodology used in testing the frailty index. Prior to
data analysis contamination between the individual items (age, symptoms, comorbidities and the
MLHFQ total score) was assessed by a careful examination of multicollinearity and residual
statistics. Because both the symptom scale and the MLHFQ contain items related to intensity of
symptoms, care was taken to assess for potential collinearity. Only when no significant issue
was found did the analysis continue. In addition, the decision to use a second unique sample
(Test sample two) to validate the findings from the first test sample (Test sample one)
strengthens the evidence supporting the findings of this study. The diversity of the samples in
which the index was tested and then validated suggests additional strength and applicability of
this index. While there were significant differences between the benchmark sample and the two
test samples in relation to functional status (NYHA class), socioeconomic status (income and
education), and ethnicity the frailty index continued to explain significant amounts of HRQOL.
Furthermore, there were differences between the two test samples. In Test sample one, health

perception’s beta coefficient (0.20) shows its relative importance in relation to the other
predictors in that regression equation, while in Test sample two, income (-0.28) has the largest
beta coefficient. This suggests that this index could be used in diverse populations. It is
recommended that further testing take place.
There are several limitations to the current study. As a secondary data analysis, the
variables available in the data set may not have been the strongest indicators of frailty. The
phenotype developed by Fried and colleagues 4 involved objective biometric measurements –
weight loss, grip strength, 15 feet walking time as well as the subjective measures of self-report
exhaustion and kilocalories expended. For our study all of the variables in the frailty index were
self-reported. It is recommended that a future, prospective longitudinal study measure the
phenotypic criteria of frailty in current use – unintentional weight loss greater than 10 pounds,
weakened grip strength, slowed pace of walking, subjective fatigue, and decreased physical
activity 4 – and compare the relationship of those indicators for frailty with HRQOL to explore
which measure is more pragmatic and predictive.
The question has been raised as to whether quality of life is better measured as an
independent or dependent variable44. What is the temporal relationship between frailty and
HRQOL? Does frailty predict HRQOL or HRQOL predict frailty? While age and number of
comorbid conditions are fixed dimensions of the patient’s experience, do the patient’s
perceptions of whether their life has quality shape their experience of physical limitations?
These questions cannot be answered with the cross sectional data in this study. Future studies
involving longitudinal measurement should explore the causal relationship between frailty and
HRQOL.

A further limitation relates to the instrument used to measure HRQOL. The Minnesota
Living with Heart Failure Questionnaire is a commonly used measure in this population48.
However, questions have been raised as to its sensitivities to subtle differences and psychometric
soundness 45, 46. A broader measure of quality of life, measuring not only health related quality
of life, but inclusive of existential and cultural domains might provide a deeper understanding of
the true impact of frailty on day to day quality of life for the older adult with HF. Finally,
secondary analysis suffers from any limitations that may have existed in the original study.
Concerns related to the validity and reliability of the measurement in the parent study, whether
concerning instrumentation or language, may call into question any findings in the secondary
analysis. However, in this analysis, the original studies were conducted by experienced and
respected researchers and were published in peer-reviewed journals.
Conclusion
Heart failure is an increasingly prevalent syndrome in the frail older adult population49.
Independently, both HF and frailty have been shown to increase the risk of repeat, unplanned
hospitalizations, increased health care costs, and death. This study has shown that frailty
negatively impacts HRQOL for the older adult with HF. As frailty increases, the negative
influences on HRQOL increase and people report lower HRQOL. As treatment preferences can
be influenced by perceived HRQOL, it is important for cardiovascular nurses to assess for frailty.
This frailty index score provides a means for the clinician to assess for frailty at the point of care.
In an older person with multiple comorbid conditions, as well as HF, reports of dyspnea, fatigue,
and pain should be addressed by nurses with evidence based symptom palliation. Recent
recommendations are available and should be integrated in to current best practice standards47.
The findings of this study also support the need for future research into the impact with frailty on

HRQOL to determine whether interventions aimed at addressing the modifiable dimensions of
the HF patient’s lived experience will improve heath related quality of life.
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Table 1.
Demographic Characteristics

Age
Gender
Male
Female
Marital status
Married
Widowed
Single
Divorced/separated
Ethnicity
Caucasian
Hispanic
Education
Less than 7th grade
Grade school
High school
Business school
2 year college
4 year college
Graduate school
Work
Homemaker
Fulltime
Part time
Disabled or retired for health reasons
Retired for non-health reasons
Unemployed
Income
Less than 10,000
10,000-14.999
15,000-19,999
20,000-29,999
30,000-44,999
45,000 or more
NYHA
II
III
IV

1
2

Benchmark
sample
n= 130
Percent Mean
(SD)
70 (13.1)
Range 39-95

Test sample one
n= 97
Percent Mean
(SD)
74 (10.9)
Range 24-91

Test sample two
n= 75
Percent Mean
(SD)
71 (11.7)
Range 20-95

54%
46%

47%
53%

43%
57%

45%
30%
8%
17%

51%
37%
3%
9%

50%
29%
7%
14%

73%
27%

98%
2%

98%
2%

28%
6%
32%
7%
16%
6%
5%

2%
9%
49%
5%
16%
11%
8%

1%
11%
51%
5%
13%
14%
5%

8%
7%
5%
25%
45%
10%

8%
2%
5%
28%
52%
5%

11%
5%
9%
30%
40%
5%

34%
26%
11%
7%
8%
14%

13%
18%
25%
22%
14%
8%

22%
22%
16%
17%
11%
12%

2%
36%
62%

13%
56%
31%

8%
48%
44%

Difference
between
Benchmark
and Sample
groups
p

0.000

0.000

0.002

0.000

Table 2.
Mean and Standard Deviations for the Frailty Index Score by Sample
Sample

1
2

Mean (SD)

N

Benchmark sample

50.98 (13.96)

130

Test sample one

39.40 (12.29)

97

Test sample two

42.32 (12.14)

75

Table 3.
Proportion of Variance and Multicollinearity Analysis
Zeroorderb

Partialc Semipartiald

Age

-0.39

-0.38

Symptoms

0.48

Comorbidity

Correlations with MLHFQ
a
total

Tolerance

Variance Inflation
Factor

-0.33

0.99

1.01

0.47

0.42

0.96

1.04

0.21

0.13

0.10

0.97

1.04

0.42

0.37

0.35

0.91

1.10

0.55

0.55

0.50

0.88

1.13

Benchmark Sample

Test sample one
Frailty Index
Test sample two
Frailty Index
1
2
3
4
5
6

a

Minnesota Living with Heart Failure Questionnaire; b zero-order correlation – raw correlation;
c
partial correlation –correlation of the given variable with MLHF total controlling for other
independent variables; d semi-partial correlation – correlation of the given variable with MLHF
total controlling only for the effect of the other independent variables on the given variable

Table 4.
Regression Analyses of Predictors of HRQOL and Frailty Index
Variable
(mean, SD)
Standardized β
t

R2

F change

p

0.11

1.73

0.14

0.24

11.03

0.001

Gender
-0.07 -0.70 0.15
2.45
Income
-0.28 -2.74
Ethnicity
-0.13 -1.26
NYHAa
-0.07 -0.74
Health Perception
0.03 0.30
Frailty Index (42.3, 13.1)
0.54 5.37 0.40
28.82
MLHFQb
(53.7, 24.8)
a
New York Heart Association, b Minnesota Living with Heart Failure Questionnaire

0.04

Test
sample
one

Test
sample
two

1
2
3
4
5
6
7
8

Gender
Income
Ethnicity
NYHA a
Health Perception
Frailty Index (39.4, 12.3)
MLHFQb
(49.6, 23.8)

0.02 0.14
-0.11 -0.94
-0.04 -0.36
0.09 0.86
-0.20 -1.83
0.37 3.32

0.000

